Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Verici Dx has developed and commercialized advanced diagnostic tests—Tutivia™ and Clarava™—for assessing the risk of acute rejection, chronic injury, and graft failure in kidney transplant patients. Tutivia™ demonstrated a significantly higher positive predictive value than existing single blood tests in an international multi-center validation study. Clarava™ showed promise in identifying pre-transplant patients at high risk of future rejection events. Protega™, a liquid biopsy test predicting fibrosis and long-term graft failure, is under development. The company’s products are offered as laboratory developed tests (LDTs) in the US under CLIA regulations; CE marking is being pursued for Europe.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Verici Dx.